Fig. 1

EYA4 is a potential novel breast cancer oncogene. A Immunohistochemistry-based H-score of normal breast tissues (n = 3) and breast carcinoma tissues (n = 12) using a validated anti-EYA4 antibody. Error bars show the medians with interquartile ranges. P value: Mann–Whitney U-test. B-G Measurement of tumor growth in xenograft mice bearing orthotopic MCF-7 control and EYA4 over-expressing tumors. B-C Tumor growth was monitored at the indicated time points by whole animal bioluminescence imaging (BLI). B Representative BLI signal of tumors is shown for weeks 1 and 8. C Quantification of the BLI signal of tumors is shown (mean ± SEM; n = 8). D-G D Tumor growth was also measured weekly using digital calipers (mean ± SEM; n = 8). E Representative images of surgically removed tumor mass are shown. Tumor (F) volume and (G) weight at week 8 are plotted (mean ± SEM; n = 8). H-I Immunohistochemistry staining of mouse MCF-7 tumors. H Representative images of surgically removed and stained tumors are shown. Low magnification (scale bar 2 mm), mid magnification (scale bar 200 μm), and high magnification views (scale bar 50 μm). Black boxes indicate the areas shown at higher magnification. I A score of negative (-), weak ( +), moderate (+ +) or strong (+ + +) was given to each stain. For all panels * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, except when indicated